Biological indicators of prognosis in Ewing's sarcoma: An emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP)

International Journal of Cancer

Volumn 126, Issue 1, 2010, Pages 41-52

  Zambelli, Diana ^a   Zuntini, Monia ^a   Nardi, Filippo ^a   Manara, Maria Cristina ^a   Serra, Massimo ^a   Landuzzi, Lorena ^a   Lollini, Pier Luigi ^b   Ferrari, Stefano ^c   Alberghini, Marco ^d   Llombart Bosch, Antonio ^e   Piccolo, Enza ^f   Iacobelli, Stefano ^f   Picci, Piero ^a   Scotlandi, Katia ^a  

^a Laboratory of Oncologic Research   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Chemotherapy   (Italy)

^d Presidio Ospedaliero di Imola   (Italy)

^e UNIVERSITY OF VALENCIA   (Spain)

^f UNIVERSITY OF CHIETI   (Italy)

Author keywords

Ewing's sarcoma; Lectin galactoside binding soluble 3 binding protein; Metastasis; Microarray analysis; Prognostic markers

Indexed keywords

CELL CYCLE PROTEIN; CELL CYCLE PROTEIN HINT1; CELL CYCLE PROTEIN IFIT2; CELL CYCLE PROTEIN LGALS3BP; CELL CYCLE PROTEIN STOML2; CISPLATIN; D 18851; DOXORUBICIN; IFOSFAMIDE; MESSENGER RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CELL CYCLE; CELL INTERACTION; CELL MATURATION; CELL MIGRATION; CONTROLLED STUDY; DRUG SENSITIVITY; EWING SARCOMA; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; MICROENVIRONMENT; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

ANIMALS; CARRIER PROTEINS; CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE SILENCING; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SARCOMA, EWING'S; SIGNAL TRANSDUCTION;

EID: 73449127619     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24670     Document Type: Article

References (45)

1. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G, Aurias A, Thomas G. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-5.
2. Barr FG, Womer RB. Molecular diagnosis of ewing family tumors: too many fusions? J Mol Diagn 2007;9:437-40.
3. Bacci G, Forni C, Longhi A, Ferrari S, Donati D, De Paolis M, Barbieri E, Pignotti E, Rosito P, Versari M. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer 2004;40:73-83.
4. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.
5. Kolb EA, Kushner BH, Gorlick R, Laverdiere C, Healey JH, LaQuaglia MP, Huvos AG, Qin J, Vu HT, Wexler L, Wolden S, Meyers PA. Long-term eventfree survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 2003;21: 3423-30.
6. Bacci G, Longhi A, Barbieri E, Ferrari S, Mercuri M, Briccoli A, Versari M, Pignotti E, Picci P. Second malignancy in 597 patients with Ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. J Pediatr Hematol Oncol 2005;27:517-20.
7. Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA, Juergens H. Ewing's sarcoma family of tumors: current management. Oncologist 2006;11: 503-19.
8. Bacci G, Longhi A, Ferrari S, Mercuri M, Versari M, Bertoni F. Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol 2006;45:469-75.
9. Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H, Craft AW. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18:3108-14.
10. Riley RD, Burchill SA, Abrams KR, Heney D, Lambert PC, Jones DR, Sutton AJ, Young B, Wailoo AJ, Lewis IJ. A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma. Health Technol Assess 2003;7:1-162.
11. Iacobelli S, Arno E, D'Orazio A, Coletti G. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res 1986;46:3005-10.
12. Koths K, Taylor E, Halenbeck R, Casipit C, Wang A. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteinerich domain. J Biol Chem 1993;268: 14245-9.
13. Iacobelli S, Sismondi P, Giai M, D'Egidio M, Tinari N, Amatetti C, Di Stefano P, Natoli C. Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br J Cancer 1994;69: 172-6.
14. Fornarini B, D'Ambrosio C, Natoli C, Tinari N, Silingardi V, Iacobelli S. Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. Blood 2000;96:3282-5.
15. Zhang DS, Ding Y, Li YH, Xu RH, Wang B, Zhang XS, Zeng J, Liang HZ, Jiang WQ. [Expression of glycoprotein 90K in non-Hodgkin's lymphoma and its clinical significance]. Ai Zheng 2005;24:1006-10.
16. Iacovazzi PA, Guerra V, Elba S, Sportelli F, Manghisi OG, Correale M. Are 90K/MAC-2BP serum levels correlated with poor prognosis in HCC patients? Preliminary results. Int J Biol Markers 2003;18:222-6.
17. Strizzi L, Muraro R, Vianale G, Natoli C, Talone L, Catalano A, Mutti L, Tassi G, Procopio A. Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival. J Pathol 2002;197:218-23.
18. Gentiloni N, Caradonna P, Costamagna G, D'Ostilio N, Perri V, Mutignani M, Febbraro S, Tinari N, Iacobelli S, Natoli C. Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. Am J Gastroenterol 1995;90: 1069-72.
19. Marchetti A, Tinari N, Buttitta F, Chella A, Angeletti CA, Sacco R, Mucilli F, Ullrich A, Iacobelli S. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res 2002;62: 2535-9.
20. Manara MC, Perdichizzi S, Serra M, Pierini R, Benini S, Hattinger CM, Astolfi A, Bagnati R, D'Incalci M, Picci P, Scotlandi K. The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71. Int J Oncol 2005;27:1605-16.
21. Scotlandi K, Manara MC, Serra M, Benini S, Maurici D, Caputo A, De Giovanni C, Lollini PL, Nanni P, Picci P, Campanacci M, Baldini N. The expression of Pglycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene 1999;18: 739-46.
22. Ullrich A, Sures I, D'Egidio M, Jallal B, Powell TJ, Herbst R, Dreps A, Azam M, Rubinstein M, Natoli C, Shawver LK, Schlessinger J, et al. The secreted tumorassociated antigen 90K is a potent immune stimulator. J Biol Chem 1994;269:18401-7.
23. Valentini AM, Iacovazzi PA, Correale M, Pirrelli M, Armentano R, Iacobelli S, Tinari N, Iurisci I, Caruso ML. Immunohistochemical and serological 90K/ Mac-2BP detection in hepatocellular carcinoma patients: different behaviour of two monoclonal antibodies. Med Chem 2005;1:185-9.
24. Manara MC, Bernard G, Lollini PL, Nanni P, Zuntini M, Landuzzi L, Benini S, Lattanzi G, Sciandra M, Serra M, Colombo MP, Bernard A, et al. CD99 acts as an oncosuppressor in osteosarcoma. Mol Biol Cell 2006;17:1910-21.
25. Cerisano V, Aalto Y, Perdichizzi S, Bernard G, Manara MC, Benini S, Cenacchi G, Preda P, Lattanzi G, Nagy B, Knuutila S, Colombo MP, et al. Molecular mechanisms of CD99-induced caspaseindependent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene 2004;23:5664-74.
26. Kojima T, Asami S, Chin M, Yoshida Y, Mugishima H, Suzuki T. Detection of chimeric genes in Ewing's sarcoma and its clinical applications. Biol Pharm Bull 2002; 25:991-4.
27. Tinari N, D'Egidio M, Iacobelli S, Bowen M, Starling G, Seachord C, Darveau R, Aruffo A. Identification of the tumor antigen 90K domains recognized by monoclonal antibodies SP2 and L3 and preparation and characterization of novel anti-90K monoclonal antibodies. Biochem Biophys Res Commun 1997;232:367-72.
28. Scotlandi K, Serra M, Nicoletti G, Vaccari M, Manara MC, Nini G, Landuzzi L, Colacci A, Bacci G, Bertoni F, Picci P, Campanacci M, et al. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res 1996;56:2434-9.
29. Goldman JP, Blundell MP, Lopes L, Kinnon C, Di Santo JP, Thrasher AJ. Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br J Haematol 1998;103:335-42.
30. Ohali A, Avigad S, Zaizov R, Ophir R, Horn-Saban S, Cohen IJ, Meller I, Kollender Y, Issakov J, Yaniv I. Prediction of high risk Ewing's sarcoma by gene expression profiling. Oncogene 2004;23: 8997-9006.
31. Schaefer KL, Eisenacher M, Braun Y, Brachwitz K, Wai DH, Dirksen U, Lanvers-Kaminsky C, Juergens H, Herrero D, Stegmaier S, Koscielniak E, Eggert A, et al. Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 2008;44: 699-709.
32. Li H, Zhang Y, Su T, Santella RM, Weinstein IB. Hint1 is a haplo-insufficient tumor suppressor in mice. Oncogene 2006; 25:713-21.
33. Yuan BZ, Jefferson AM, Popescu NC, Reynolds SH. Aberrant gene expression in human non small cell lung carcinoma cells exposed to demethylating agent 5-aza-2′-deoxycytidine. Neoplasia 2004;6:412-19.
34. Weiske J, Huber O. The histidine triad protein Hint1 triggers apoptosis independent of its enzymatic activity. J Biol Chem 2006;281:27356-66.
35. Weiske J, Huber O. The histidine triad protein Hint1 interacts with Pontin and Reptin and inhibits TCF-beta-cateninmediated transcription. J Cell Sci 2005;118: 3117-29.
36. Sollazzo MR, Benassi MS, Magagnoli G, Gamberi G, Molendini L, Ragazzini P, Merli M, Ferrari C, Balladelli A, Picci P. Increased c-myc oncogene expression in Ewing's sarcoma: correlation with Ki67 proliferation index. Tumori 1999;85: 167-73.
37. Momota H, Shih AH, Edgar MA, Holland EC. c-Myc and beta-catenin cooperate with loss of p53 to generate multiple members of the primitive neuroectodermal tumor family in mice. Oncogene 2008;27: 4392-401.
38. Andreu P, Colnot S, Godard C, Laurent-Puig P, Lamarque D, KahnA, Perret C, Romagnolo B. Identification of the IFITMfamily as a new molecularmarker in human colorectal tumors. Cancer Res 2006; 66:1949-55.
39. Cao WF, Zhang LY, Liu MB, Tang PZ, Liu ZH, Sun BC. Prognostic significance of stomatin-like protein 2 overexpression in laryngeal squamous cell carcinoma: clinical, histologic, and immunohistochemistry analyses with tissue microarray. Hum Pathol 2007;38:747-52.
40. Zhang L, Ding F, Cao W, Liu Z, Liu W, Yu Z, Wu Y, Li W, Li Y, Liu Z. Stomatinlike protein 2 is overexpressed in cancer and involved in regulating cell growth and cell adhesion in human esophageal squamous cell carcinoma. Clin Cancer Res 2006;12:1639-46.
41. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer 2005;5:29-41.
42. Elola MT, Wolfenstein-Todel C, Troncoso MF, Vasta GR, Rabinovich GA. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci 2007;64: 1679-700.
43. Grassadonia A, Tinari N, Iurisci I, Piccolo E, Cumashi A, Innominato P, D'Egidio M, Natoli C, Piantelli M, Iacobelli S. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J 2004;19:551-6.
44. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007;11: 421-9.
45. Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR, Lessnick SL. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 2006;9:405-16.